## Program

### FRIDAY, 6 September – Pre-conference Education Course

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>Walk in coffee</td>
</tr>
<tr>
<td>9:30 AM</td>
<td><strong>Parallel sessions - Integrated training on:</strong></td>
</tr>
<tr>
<td></td>
<td>• Ultrasonography</td>
</tr>
<tr>
<td></td>
<td>• Endoscopy</td>
</tr>
<tr>
<td></td>
<td>• Point of care testing</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Program break - Friday afternoon prayer</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Lunch</td>
</tr>
<tr>
<td>2:00 PM</td>
<td><strong>Opening of the conference</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Manal El-Sayed, MD, PhD &amp; Ayman Yosry, MD</em></td>
</tr>
<tr>
<td>2:15 PM</td>
<td><strong>Keynote lecture: Global efforts on viral hepatitis elimination</strong></td>
</tr>
<tr>
<td></td>
<td><em>John Ward, MD</em></td>
</tr>
<tr>
<td></td>
<td><em>Centers for Disease Control, USA</em></td>
</tr>
<tr>
<td>2:45 PM</td>
<td><strong>What’s new in viral hepatitis - including EASL coverage</strong></td>
</tr>
<tr>
<td></td>
<td><em>Thomas Berg, MD</em></td>
</tr>
<tr>
<td></td>
<td><em>University Hospital Leipzig, Germany</em></td>
</tr>
<tr>
<td>3:15 PM</td>
<td><strong>Viral hepatitis and pregnancy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Wendy Spearman, MD, PhD</em></td>
</tr>
<tr>
<td></td>
<td><em>University of Cape Town, South Africa</em></td>
</tr>
<tr>
<td>3:45 PM</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Break</td>
</tr>
</tbody>
</table>

### Session 1 - HCC and its management

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 PM</td>
<td><strong>Epidemiology, burden of disease and outcomes of HCC in Africa</strong></td>
</tr>
<tr>
<td></td>
<td><em>Edith Okeke, MD</em></td>
</tr>
<tr>
<td></td>
<td><em>University of Jos, Nigeria</em></td>
</tr>
<tr>
<td>4:55 PM</td>
<td><strong>Improving risk stratification and early detection of HCC in Africa</strong></td>
</tr>
<tr>
<td></td>
<td><em>Ashraf Omar, MD</em></td>
</tr>
<tr>
<td></td>
<td><em>Cairo University, Egypt</em></td>
</tr>
<tr>
<td>5:20 PM</td>
<td><strong>Surgical therapy for HCC – including resection and liver transplantation</strong></td>
</tr>
<tr>
<td></td>
<td><em>Mahmoud El-Meteini, MD, M.B.B.Ch</em></td>
</tr>
<tr>
<td></td>
<td><em>Ain Shams University, Egypt</em></td>
</tr>
<tr>
<td>5:45 PM</td>
<td><strong>Loco-regional therapy for HCC – including ablation, chemoembolization and hepatic artery embolization</strong></td>
</tr>
<tr>
<td></td>
<td><em>Benjamin Sarkodie, MD</em></td>
</tr>
<tr>
<td></td>
<td><em>University of Ghana School of Medicine &amp; Dentistry, Ghana</em></td>
</tr>
</tbody>
</table>
6:10 PM  **Systemic therapy – what is realistic in the LMIC setting?**  
**Mitesh Borad, MD**  
Mayo Clinic Arizona, USA

6:35 PM  **Needs for research and advocacy for HCC in Africa**  
**Olufunmilayo Lesi, FWACP, FMCP**  
WHO Regional Office for Africa, Congo

Discussion

7:00 PM  Welcome reception

**SATURDAY, 7 September**

8:00 AM  **Industry Supported Symposium I - Gilead**

**Session 2  Management of viral hepatitis (I) - HBV related**  
*Chairs: Wendy Spearman MD, PhD & Thomas Berg, MD*

9:00 AM  **Simplification of HBV treatment algorithm**  
**Ayman Yosry, MD**  
Cairo University, Egypt

9:25 AM  **Treatment of HBV in sub-Saharan Africa**  
**Hailemichael Desalegn, MD**  
St. Paul’s Hospital Millennium Medical College, Ethiopia

**Abstract-driven presentations:**

9:50 AM  Prevalence of Hepatitis B Surface Antigen (HBsAg) positivity and its associated factors in Rwanda/risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program  
Jean Damascene Makuza  
#01-A/#01-B

10:00 AM  Prenatal consultation as a starting point for family screening of hepatitis B virus, the CI cohort ANRS 12359  
Nanelin Alice Guingane  
#02

10:10 AM  Analysis of the National Hepatitis B Viral Load Testing Programme in Uganda  
Viola Kasone  
#03

10:20 AM  High rates of HBV functional cure among HIV/HBV-coinfected patients on ART in Zambia  
Michael Vinikoor  
#04

10:30 AM  Break
Session 3  Management of viral hepatitis (II) - HCV related  
*Chairs: Mark Nelson, MD, FRCP & Mary Afihene MBChB, FWACP*

11:00 AM  **Treatment of hepatitis C in SSA (Rwanda)**  
Neil Gupta, MD  
Harvard Medical School, USA

11:25 AM  **Hepatitis delta**  
Mario Rizetto, MD  
University of Torino, Italy

Abstract-driven presentations:

11:50 AM  Hepatitis C treatment among people who inject drugs in Kenya: preliminary findings of the test and link to care for injecting drug users study C infection in Rwanda: results from a nationwide screening program  
Mercy Nyakowa #05

12:00 PM  Efficacy of Direct-Acting Antiviral (DAA) regimens in HIV/HCV-co-infected patients in Libya  
Nagat Bousifi #06

12:10 PM  Assessment of liver fibrosis after Direct-Acting Antiviral therapy in compensated and decompensated HCV-related liver diseases  
Mohammed Mohammed #07

12:20 PM  Heading toward hepatitis C virus elimination: Tunisian experience, achievements and prospects  
Mouna Safer #08

12:30 PM  Lunch

1:15 PM  **Get your paper published in The Lancet**  
Robert Brierley  
The Lancet Gastroenterology & Hepatology, United Kingdom

1:45 PM  **HBV Cure Science 101 - organized by ICE-HBV**  
Anna Kramvis, BScHons, PhD  
International Coalition to Eliminate HBV (ICE-HBV) / University of the Witwatersrand, South Africa

Session 4  Public health - Egypt’s model of care  
*Chairs: Gamal Esmat, MD & John Ward, MD*

2:45 PM  **Screening of 50 million people**  
Manal El-Sayed, MD, PhD  
Ain Shams University, Egypt

3:05 PM  **Scaling up treatment**  
Wahid Doss, MD  
Cairo University, Egypt
3:25 PM  **Round Table discussion: Translation of Egypt’s experience to the rest of Africa**

- Wahid Doss, MD - Cairo University, Egypt
- Gamal Esmat, MD - Cairo University, Egypt
- Magdy El-Serafy, MD - Cairo University, Egypt
- Imam Waked, MB, BCh, MSc, MD, FAASLD - National Liver Institute, Egypt
- Mohamed Hassany, MD - National Hepatology and Tropical Medicine Research Institute, Egypt

4:10 PM  **Break**

### Session 5

**Civil society contribution in Africa - organized by World Hepatitis Alliance**

*Chairs: Cary James & Gamal Shiha, MD, MBBH, MSc*

4:40 PM  **Round table Discussion: the role of patient support groups**

- Cary James - World Hepatitis Alliance, United Kingdom
- Bisi Bright - LiveWell Initiative LWI, Nigeria
- Mohamed El-Wahsh - Tanya Masr, Egypt
- Ammal Metwally, MD, PhD - National Research Center, Egypt
- Coulibaly Alioune Badara, MD - Association pour la Promotion de la Sante et le Developpement (APSAD), Mali
- Kenneth Kabagambe, BA - The National Organisation for People Living with Hepatitis B (NOPLHB), Uganda
- Elodie Sanasee - Prévention Information et Lutte contre le SIDA (PILS), Mauritius

---

**SUNDAY, 8 September**

8:00 AM  **Industry Supported Symposium II: Economic impact and funding for hepatitis elimination - drawing from Egypt’s success**

### Session 6

**NASH/NAFLD management in Africa**

*Chairs: John Rwegasha MBChB, M.MED, FRCP, MSc & Imam Waked, MB, BCh, MSc, MD, FAASLD*

9:00 AM  **New therapies for NASH/NAFLD**

- Thomas Berg, MD
  - University Hospital Leipzig, Germany

9:30 AM  **Clinical case presentation**

- Imam Waked, MB, BCh, MSc, MD, FAASLD
  - National Liver Institute, Egypt

*Abstract - driven presentations:*

10:00 AM  **HCC developed following DAAs treatment does not display more aggressive pattern**

- Gamal Shiha  #09

10:10 AM  **Factors associated with liver toxicity among HIV infected children and adolescents attending a national referral pediatric HIV clinic in Uganda**

- Bonny Mulindwa  #10

10:20 AM  **Prevalence of fatty liver disease and associated factors among outpatients attending internal medicine clinics at Muhimbili University of Health and Allied Sciences Academic Medical Centre, Tanzania**

- Nontobeko Simelane  #11
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:30 AM | **Best of Posters**  
*Chairs: Mark Nelson, MD, FRCP & Manal El-Sayed, MD, PhD* |
| 11:00 AM | Break |
| 11:30 AM | **Industry Supported Symposium III - Pharco:**  
*Innovation of access to treatment: Real Life Scenarios* |
| 1:00 PM | Lunch |

**Session 7**  
WHO sponsored session on viral hepatitis and universal health coverage

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 2:00 PM | **The global and regional hepatitis elimination agenda**  
*Joumana Hermez*  
WHO/EMRO, Egypt |
| 2:10 PM | **Access to hepatitis B and C medicines**  
*Othman Mellouk, MD*  
International Treatment Preparedness Coalition (ITPC), Morocco |
| 2:20 PM | **Leaving no one behind: role of civil society in reaching people who inject drugs (PWID) for hepatitis elimination**  
*Elie Aaraj*  
Middle East and North Africa Harm Reduction Association (MENAHRA), Lebanon |
| 2:30 PM | **Innovative financing and financial protection: inclusion of viral hepatitis services**  
*Awad Mataria, PhD*  
WHO/EMRO, Egypt |
| 2:40 PM | **Fitting viral hepatitis elimination in the UHC agenda**  
WHO/EMRO, Egypt |
| 2:45 PM | Discussion |
| 3:30 PM | **Closure of the conference** |

Shortly after the workshop, presentations will be posted on [www.I-MedNet.com](http://www.I-MedNet.com)